» Authors » Nallakkandi Rajeevan

Nallakkandi Rajeevan

Explore the profile of Nallakkandi Rajeevan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 1643
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, et al.
Ann Intern Med . 2025 Feb; PMID: 39903865
Background: Monovalent COVID-19 vaccines targeting the XBB.1.5 Omicron variant were introduced in September 2023. In the absence of randomized controlled trials demonstrating their efficacy, information on real-world vaccine effectiveness (VE)...
2.
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, et al.
JAMA Intern Med . 2025 Jan; 185(3):324-334. PMID: 39869355
Importance: SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) contribute to many hospitalizations and deaths each year. Understanding relative disease severity can help to inform vaccination guidance. Objective: To compare disease...
3.
Bajema K, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, et al.
Lancet Infect Dis . 2025 Jan; PMID: 39848264
Background: New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information...
4.
Bui D, Bajema K, Huang Y, Yan L, Li Y, Rajeevan N, et al.
PLoS One . 2024 Oct; 19(10):e0307235. PMID: 39365775
Objective: The epidemiology of COVID-19 has substantially changed since its emergence given the availability of effective vaccines, circulation of different viral variants, and re-infections. We aimed to develop models to...
5.
Bigdeli T, Chatzinakos C, Bendl J, Barr P, Venkatesh S, Gorman B, et al.
medRxiv . 2024 Sep; PMID: 39252912
Large-scale genome-wide association studies of schizophrenia have uncovered hundreds of associated loci but with extremely limited representation of African diaspora populations. We surveyed electronic health records of 200,000 individuals of...
6.
Yan L, Bui D, Li Y, Rajeevan N, Rowneki M, Berry K, et al.
Clin Infect Dis . 2024 Jun; 79(3):643-651. PMID: 38864601
Background: Nirmatrelvir-ritonavir is recommended for persons at risk for severe coronavirus disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups are likely to benefit from treatment is needed....
7.
Bigdeli T, Barr P, Rajeevan N, Graham D, Li Y, Meyers J, et al.
Mol Psychiatry . 2024 Mar; 29(8):2399-2407. PMID: 38491344
Persons diagnosed with schizophrenia (SCZ) or bipolar I disorder (BPI) are at high risk for self-injurious behavior, suicidal ideation, and suicidal behaviors (SB). Characterizing associations between diagnosed health problems, prior...
8.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, et al.
Ann Intern Med . 2023 Oct; 176(11):1486-1497. PMID: 37903369
Background: COVID-19 has been linked to the development of many post-COVID-19 conditions (PCCs) after acute infection. Limited information is available on the effectiveness of oral antivirals used to treat acute...
9.
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, et al.
J Investig Med . 2023 Sep; 72(1):139-150. PMID: 37668313
Affecting an estimated 88 million Americans, prediabetes increases the risk for developing type 2 diabetes mellitus (T2DM), and independently, cardiovascular disease, retinopathy, nephropathy, and neuropathy. Nevertheless, little is known about...
10.
Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, et al.
JAMA Netw Open . 2023 Aug; 6(8):e2331249. PMID: 37651140
Importance: Several pharmacotherapies have been authorized to treat nonhospitalized persons with symptomatic COVID-19. Longitudinal information on the use of these therapies is needed. Objective: To analyze trends and factors associated...